Table 4.

Variables associated with endocrine therapy (ET) continuation for at least 12 months after initiation, stratified by race

	aOR (95% CI)a
Independent variables	White (n = 248)	Blackb (n = 157)	Black/Other (n = 162)
Age, years	0.96 (0.92-1.01)	0.98 (0.92-1.04)	0.98 (0.92-1.04)
Insurance status
Private	Ref	Ref	Ref
Public only or otherc	5.87 (0.36-94.67)	0.54 (0.18-1.57)	0.54 (0.19-1.58)
Chemotherapy
No	Ref	Ref	Ref
Yes	1.16 (0.39-3.46)	1.58 (0.54-4.58)	1.58 (0.54-4.57)
Radiation Therapy
No	Ref	Ref	Ref
Yes	1.62 (0.66-3.99)	1.12 (0.35-3.55)	1.16 (0.37-3.68)
Diabetes
No	Ref	Ref	Ref
Yes	0.49 (0.13-1.87)	1.23 (0.39-3.87)	1.19 (0.38-3.74)
Obesity
No (BMI < 30 kg/m2)	Ref	Ref	Ref
Yes (BMI ≥ 30 kg/m2)	1.20 (0.45-3.19)	0.85 (0.32-2.26)	0.83 (0.31-2.19)
Elevated depressed mood
No (CESD < 16)	Ref	Ref	Ref
Yes (CESD ≥16)	0.24 (0.07-0.78)*	0.96 (0.28-3.27)	0.94 (0.28-3.23)
Menopausal-symptom severity	0.66 (0.41-1.07)	0.72 (0.39-1.32)	0.70 (0.38-1.30)
Change in menopausal-symptom severity mean scoresd	0.77 (0.42-1.43)	1.42 (0.74-2.73)	1.40 (0.73-2.69)

BMI body mass index, aOR adjusted odds ratio, CI confidence interval, CESD Center for Epidemiologic Studies Depression scale

^a Using diabetes, obesity, elevated depressed mood, and menopausal symptom data from the interview when ET initiation was first reported

^b Five patients (two Asian Indian/Pakistani, one Asian/Pacific Islander, and two unspecified because they did not respond to the question about race) were excluded from this sensitivity analysis stratified by race to compare the associations between ET continuation and variables of interest within each racial group

^c Other insurance status includes no insurance or self-pay

^d Change in menopausal-symptom severity mean scores from patient’s first reported use of ET to 12-18 month follow-up of ET continuation among patients who had used ET within 12 months of definitive surgery

^* P < 0.05